Functional Concept

AnaptysBio Halts Phase 2 Ulcerative Colitis Trial; Lyell Immunopharma Secures CAR-T Rights

2 days ago talkbio0Tagged AnaptysBio, CAR-T therapy, Clinical Failure, Clinical Trials, Discontinuation (procedure), Lyell Immunopharma, News [Publication Type], Phase 2 trial, Rheumatoid Arthritis, Rosnilimab, Ulcerative Colitis

AnaptysBio; rosnilimab; ulcerative colitis; Phase 2 trial; clinical failure; trial discontinuation; Lyell Immunopharma; CAR-T therapy; licensing deal; biotech news; rheumatoid arthritis

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

2 days ago talkbio0Tagged Capitalization, clinical-stage biopharma, development aspects, exophthalmos producing substance, financial results, Impaired, Market, net loss, Nkarta, Operating expenses, Q3, research

Nkarta; Q3 2025 financial results; net loss; operating expenses; EPS; research and development; impairment; market capitalization; clinical-stage biopharma; corporate highlights

Recent News on Upcoming and On-Demand Webinars (November 2025)

3 days ago talkbio0Tagged business career, Event, Intrathecal Route of Drug Administration, nonprofit webinars, November 2025, On-Demand Webinars, webinar calendar, webinars

upcoming webinars; on-demand webinars; webinar calendar; November 2025 events; nonprofit webinars; IT webinars; business webinars

Eli Lilly Hires Denali Therapeutics Executive Carole Ho to Lead Neuroscience Division

3 days ago talkbio0Tagged Biological Factors, Carole Ho, Changing, Denali, eli lilly, executive leadership, Leadership, neuroscience division

Eli Lilly; Denali Therapeutics; Carole Ho; neuroscience division; executive leadership; biopharmaceuticals; leadership changes

Maximizing ROI with Educational Content for Healthcare Marketers: 2025 Trends and Strategies

6 days ago talkbio0Tagged Cell Differentiation process, Data Analytics, digital strategies, Educational content, Feeling content, Health Care Market, Market, Marketing, Metric (substance), Patient Engagement, Performance, personalization, POC, point-of-care, Region of interest:Presence or Identity:Point in time:*:Nominal

healthcare marketing; educational content; ROI; patient engagement; data analytics; AI personalization; point-of-care (POC) marketing; digital strategies; market differentiation; content performance metrics

Eisai Expands Leqembi Subcutaneous Label, Accelerates Early U.S. Launch Progress for Alzheimer’s Disease

6 days ago talkbio0Tagged Alzheimer 's disease, at-home injection, dosing, Eisai, expansion, Labels (device), Leqembi, Maintenance, sBLA, starting dose, status - In progress, Subcutaneous Autoinjector, supplemental biologics, United States Food and Drug Administration

Eisai; Leqembi; subcutaneous autoinjector; label expansion; Supplemental Biologics License Application (sBLA); FDA; maintenance dosing; starting dose; early Alzheimer’s disease; at-home injection; launch progress

Spotlight On Obesity Week: Non-incretin Alternatives Turn Up the Heat

6 days ago talkbio0Tagged Adherence (attribute), Behavior, cardiometabolic, Contrave, craving control, Health, naltrexone-bupropion, non-incretin therapies, pharmaceutical innovation, Weight maintenance regimen

ObesityWeek 2025; non-incretin therapies; naltrexone-bupropion; CONTRAVE; weight management; craving control; behavioral adherence; pharmaceutical innovation; cardiometabolic health

FluoGuide Strengthens Leadership to Drive Clinical and Regulatory Advancements

1 week ago talkbio0Tagged board of directors, Camilla Harder Hartvig, Changing, Chief Operating Officer, Clinical Development, Donna Haire, FluoGuide, Leadership, precision cancer, regulatory approval

FluoGuide; leadership changes; Donna Haire; Chief Operating Officer; Camilla Harder Hartvig; Board of Directors; FG001; clinical development; regulatory approval; precision cancer surgery

Metsera Bidding War Grips Obesity Drug Field as Novo Nordisk and Pfizer Escalate Offers

1 week ago talkbio0Tagged Acquisition, Antitrust, bidding war, Disputes, Dominance, Glucagon-Like Peptide 1, Legal, Market, Metsera, Novo Nordisk, Obesity, Pfizer

Metsera; obesity drugs; bidding war; Novo Nordisk; Pfizer; acquisition; GLP-1; antitrust; market dominance; legal disputes

Sarepta’s Duchenne Muscular Dystrophy Drugs Fail Confirmatory Trial, Company Pursues Full FDA Approval Regardless

1 week ago talkbio0Tagged Accelerated, AMONDYS, Approved, Clinical trial failure, Confirmatory Trial, ELEVIDYS, Muscular Dystrophy, Duchenne, Statistical Significance, United States Food and Drug Administration

Sarepta Therapeutics; Duchenne muscular dystrophy; confirmatory trial; AMONDYS 45; VYONDYS 53; Elevidys; FDA approval; clinical trial failure; accelerated approval; statistical significance